FINWIRES · TerminalLIVE
FINWIRES

SHA:688278

8 stories mentioning SHA:688278Updated 10d ago

Every FINWIRES story that references SHA:688278, newest first.

What's the latest news on SHA:688278?

Asia

Xiamen Amoytop Biotech to Invest 100 Million Yuan in AI Fund

Xiamen Amoytop Biotech (SHA:688278) will invest 100 million yuan as a limited partner in an artificial intelligence fund, according to a Saturday filing with the Shanghai bourse.The Tianjin Lisi Xingshen Equity Investment Partnership, a fund that will invest in early- to mid-stage unlisted companies in artificial intelligence-related fields, aims to raise at least 3 billion yuan.Director Lan Bolin also plans to contribute 200 million yuan to the partnership.

SHA:688278
Treasury

Amoytop Biotech Adjusts Fund Allocation After Fundraising Shortfall

Xiamen Amoytop Biotech (SHA:688278) adjusted the proposed investment amounts for its convertible bond fundraising projects, following a net proceeds shortfall.Net proceeds came to 1.52 billion yuan, lower than the planned 1.53 billion yuan, according to a Wednesday filing with the Shanghai bourse.The adjustments affect the Biotech innovation integration center project, which saw its allocation reduced to 446.2 million yuan from 461.9 million yuan.Shares of the drugmaker were up 7% Wednesday.

SHA:688278
Treasury

Amoytop Biotech Launches 1.53 Billion-Yuan Convertible Bond Offering

Xiamen Amoytop Biotech (SHA:688278) on Tuesday launched a convertible bond issue of 1.53 billion yuan, according to a Tuesday filing with the Shanghai bourse.Guojin Securities serves as lead underwriter, with CICC as joint lead underwriter. The bond issue carries a 30% maximum underwriter liability cap of 460.0 million yuan.Shares of the drugmaker were down 4% in recent trade.

SHA:688278
Asia

Amoytop to Offer 1.53 Billion Yuan Worth of Convertible Bonds

Xiamen Amoytop Biotech (SHA:688278) plans to offer and issue convertible bonds worth 1.53 billion yuan, according to a Friday disclosure on the Shanghai bourse.The Chinese drugmaker will offer the Amoytop Convertible Bond on July 28, preferentially allotted to shareholders on the record by July 27.

SHA:688278
Asia

Amoytop Biotech Gets Chinese Regulatory Nod for Hepatitis B Drug Trial

Xiamen Amoytop Biotech (SHA:688278) received approval from China's National Medical Products Administration for the clinical trial of ACT201 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for chronic hepatitis B.The drugmaker's shares rose 3% at the close.

SHA:688278
Asia

Chinese Drug Regulator Accepts Amoytop Biotech's Clinical Trial Application for ACT201 Injection

China's National Medical Products Administration accepted Xiamen Amoytop Biotech's (SHA:688278) clinical trial application for ACT201 injection, according to a Shanghai bourse filing on Thursday.The drug, an antisense oligonucleotide drug, will be used as a treatment for hepatitis B.The drugmaker's shares rose 2% during the midday trade.

SHA:688278
Asia

Amoytop Biotech to Raise Up to 1.5 Billion Yuan from Convertible Bond Issuance

Xiamen Amoytop Biotech (SHA:688278) plans to raise funds of up to 1.53 billion yuan from the issuance of convertible bonds, according to a Thursday disclosure on the Shanghai bourse.The proceeds will be used to invest in a new drug research and development project, a biotechnology innovation center project and the construction of a production line.

SHA:688278
Asia

Xiamen Amoytop Biotech Signs License Deal for Hepatitis B Drug

Xiamen Amoytop Biotech (SHA:688278) signed an exclusive license agreement with Aligos Therapeutics for pevifoscorvir sodium, used for treating chronic hepatitis B.Amoytop will pay an upfront $25 million, plus up to $85 million in regulatory and $335 million in sales milestones, plus royalties, according to a Friday filing with the Shanghai bourse.The deal covers Mainland China, Hong Kong, Macao and Taiwan.Shares of the drugmaker closed 1% lower Friday.

SHA:688278

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:688278 in your portfolio
WheelAI
WheelAI
Analyze SHA:688278 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:688278